골관절염 환자에서 경구용 소염진통제의 장기사용에 따른 전신 부작용의 위험을 줄이기 위한 필요성으로 국소형 진통소염제가 개발되었으며, 그 중 piroxicam을 주성분으로 하면서 기타 보조성분들을 이용하여 경피흡수율을 높이고, 통증부위에서의 지속적인 약물농도를 유지하도록 하는 트라스트 패취가 기존에 유용하게 사용되어 왔다. 무르페는 트라스트와 동일한 주성분을 사용하되 새로운 흡수제와 용해제 등을 사용하여 임상효과의 향진을 시도한 새로운 패취로, 본 연구에서는 무르페와 트라스트를 사용하여 골관절염 환자에서 임상효과를 평가하기 위한 비교 연구를 시행하였다. 무르페는 1, 2차 유효성 평가 변수에서 모두 일관되게 트라스트에 비하여 우수한 통증감소 효과가 있으면서, 국소 및 전신 이상반응은 더 높지 않은 결과를 보여주었다. 무르페와 같은 패취형 NSAID의 사용이 무릎 골관절 염 환자의 유용한 치료가 될 수 있을 것으로 생각되며, 패취제의 개발 시 적절한 보조제의 사용은 NSAID 국소 요법의 효능과 안전성을 높일 수 있을 것으로 판단된다.
골관절염 환자에서 경구용 소염진통제의 장기사용에 따른 전신 부작용의 위험을 줄이기 위한 필요성으로 국소형 진통소염제가 개발되었으며, 그 중 piroxicam을 주성분으로 하면서 기타 보조성분들을 이용하여 경피흡수율을 높이고, 통증부위에서의 지속적인 약물농도를 유지하도록 하는 트라스트 패취가 기존에 유용하게 사용되어 왔다. 무르페는 트라스트와 동일한 주성분을 사용하되 새로운 흡수제와 용해제 등을 사용하여 임상효과의 향진을 시도한 새로운 패취로, 본 연구에서는 무르페와 트라스트를 사용하여 골관절염 환자에서 임상효과를 평가하기 위한 비교 연구를 시행하였다. 무르페는 1, 2차 유효성 평가 변수에서 모두 일관되게 트라스트에 비하여 우수한 통증감소 효과가 있으면서, 국소 및 전신 이상반응은 더 높지 않은 결과를 보여주었다. 무르페와 같은 패취형 NSAID의 사용이 무릎 골관절 염 환자의 유용한 치료가 될 수 있을 것으로 생각되며, 패취제의 개발 시 적절한 보조제의 사용은 NSAID 국소 요법의 효능과 안전성을 높일 수 있을 것으로 판단된다.
Background/Aims : We wanted to compare the efficacy and safety of a Murupe® patch, which is a newly-developed piroxicam patch, with the Trast® patch for the treatment of knee osteoarthritis. Methods : Two hundred ten patients with radiologically confirmed symptomatic osteoarthritis of the knee were ...
Background/Aims : We wanted to compare the efficacy and safety of a Murupe® patch, which is a newly-developed piroxicam patch, with the Trast® patch for the treatment of knee osteoarthritis. Methods : Two hundred ten patients with radiologically confirmed symptomatic osteoarthritis of the knee were included in a randomized, open-labeled controlled trial and they were treated with a 48 mg piroxicam patch once every 48 hours for 4 weeks. The main outcome measures were the pain intensity on movement and the spontaneous pain intensity during rest, and these were measured using the 10 cm Visual Analogue Scale (VAS) categorical pain scores, as measured by the patient and the investigator. Results : One hundred sixty-seven of the 210 enrolled patients completed the 4 week study. The pain intensity on movement was significantly reduced in both the Trast® and Murupe® groups (p<0.001) after 4 weeks of treatment; the improvement on the VAS was significantly higher in the Murupe® group (n=82) than that in the Trast® group (n=85) (4.5 cm versus 2.2 cm, respectively, p<0.001). Both treatment groups also showed reductions in all the other parameters of pain intensity, including spontaneous pain intensity during rest, the categorical pain scores and the 15 meter-walking time. There was no difference in adverse events between both groups. Conclusions : The superior analgesic activity of Murupe® patch indicates that the topical route of non-steroidal anti-inflammatory drug (NSAID) administration may be a safe, effective alternative to the oral route for the treatment of knee OA, and that the newly developed NSAID patch with its improved transdermal drug delivery may increase the efficacy of topical NSAIDs.
Background/Aims : We wanted to compare the efficacy and safety of a Murupe® patch, which is a newly-developed piroxicam patch, with the Trast® patch for the treatment of knee osteoarthritis. Methods : Two hundred ten patients with radiologically confirmed symptomatic osteoarthritis of the knee were included in a randomized, open-labeled controlled trial and they were treated with a 48 mg piroxicam patch once every 48 hours for 4 weeks. The main outcome measures were the pain intensity on movement and the spontaneous pain intensity during rest, and these were measured using the 10 cm Visual Analogue Scale (VAS) categorical pain scores, as measured by the patient and the investigator. Results : One hundred sixty-seven of the 210 enrolled patients completed the 4 week study. The pain intensity on movement was significantly reduced in both the Trast® and Murupe® groups (p<0.001) after 4 weeks of treatment; the improvement on the VAS was significantly higher in the Murupe® group (n=82) than that in the Trast® group (n=85) (4.5 cm versus 2.2 cm, respectively, p<0.001). Both treatment groups also showed reductions in all the other parameters of pain intensity, including spontaneous pain intensity during rest, the categorical pain scores and the 15 meter-walking time. There was no difference in adverse events between both groups. Conclusions : The superior analgesic activity of Murupe® patch indicates that the topical route of non-steroidal anti-inflammatory drug (NSAID) administration may be a safe, effective alternative to the oral route for the treatment of knee OA, and that the newly developed NSAID patch with its improved transdermal drug delivery may increase the efficacy of topical NSAIDs.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.